Published in Cancer Res on June 03, 2015
miR-181a induces sorafenib resistance of hepatocellular carinoma cells through downregulation of RASSF1 expression. Cancer Sci (2016) 0.79
MicroRNA-155 and Its Role in Malignant Hematopoiesis. Biomark Insights (2015) 0.78
The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene? PLoS Genet (2017) 0.77
Proof-of-concept study: profile of circulating microRNAs in Bovine serum harvested during acute and persistent FMDV infection. Virol J (2017) 0.75
Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells. Int J Oncol (2015) 0.75
Excess of a Rassf1-targeting microRNA, miR-193a-3p, perturbs cell division fidelity. Br J Cancer (2017) 0.75
RNA binding protein CUGBP1 inhibits liver cancer in a phosphorylation dependent manner. Mol Cell Biol (2017) 0.75
miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer. Cell Death Dis (2017) 0.75
MicroRNAs: target recognition and regulatory functions. Cell (2009) 92.17
MicroRNAs modulate hematopoietic lineage differentiation. Science (2003) 30.05
A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell (2005) 9.22
miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell (2007) 9.08
The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell (1991) 8.98
Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science (2002) 6.05
Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res (2006) 5.72
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Acute promyelocytic leukemia: from highly fatal to highly curable. Blood (2008) 5.35
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood (1999) 4.58
The microcosmos of cancer. Nature (2012) 4.50
CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A (2007) 4.06
PML is essential for multiple apoptotic pathways. Nat Genet (1998) 3.75
MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood (2008) 3.50
Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A (2008) 3.13
The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell (1993) 2.96
The RASSF1A tumor suppressor. J Cell Sci (2007) 2.89
Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res (2005) 2.86
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene (2007) 2.79
Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun (2006) 2.65
TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene (2009) 2.33
High-penetrance mouse model of acute promyelocytic leukemia with very low levels of PML-RARalpha expression. Blood (2003) 2.26
Cell-cycle regulator E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in acute myeloid leukemia. Blood (2009) 2.26
The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol (2002) 2.19
Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid. Blood (1981) 2.16
MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia (2007) 2.05
Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem (2000) 2.02
C/EBPbeta: a major PML-RARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J (2003) 1.58
miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis (2012) 1.45
miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood (2011) 1.44
Functional analysis of microRNAs in human hepatocellular cancer stem cells. J Cell Mol Med (2012) 1.35
Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood (2008) 1.30
Chromatin modifications induced by PML-RARalpha repress critical targets in leukemogenesis as analyzed by ChIP-Chip. Blood (2007) 1.28
C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. Blood (2010) 1.28
MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene (2014) 1.16
Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leuk Lymphoma (2010) 1.13
NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia (2014) 1.07
A restricted signature of miRNAs distinguishes APL blasts from normal promyelocytes. Oncogene (2009) 1.05
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood (2012) 1.04
Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol (2005) 0.98
Reconstructing a disease: What essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell (2006) 0.96
MicroRNAs: new players in acute myeloid leukaemia. Br J Cancer (2009) 0.93
Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J Biol Chem (2002) 0.92
Transcription factor C/EBPα-induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. Blood (2013) 0.91
RASSF1A suppresses melanoma development by modulating apoptosis and cell-cycle progression. J Cell Physiol (2011) 0.89
Activation of the p38 MAPK/Akt/ERK1/2 signal pathways is required for the protein stabilization of CDC6 and cyclin D1 in low-dose arsenite-induced cell proliferation. J Cell Biochem (2010) 0.88
Proteomic analysis of acute promyelocytic leukemia: PML-RARalpha leads to decreased phosphorylation of OP18 at serine 63. Proteomics (2006) 0.85
Role of microRNAs in myeloid differentiation. Biochem Soc Trans (2008) 0.83
Intact expression status of RASSF1A in acute myeloid leukemia. Med Oncol (2013) 0.78
In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia. J Hematol Oncol (2015) 0.80
The Janus-faced Nature of miR-22 in Hematopoiesis: Is It an Oncogenic Tumor Suppressor or Rather a Tumor-Suppressive Oncogene? PLoS Genet (2017) 0.77
Baricitinib restrains the immune dysregulation in severe COVID-19 patients. J Clin Invest (2020) 0.75